Protocol # ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Medically Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV
-
Sponsor: ADMA Biologics, Inc.
Location(s): United States
Description
RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being infected with RSV in the upper respiratory tract.